Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors

Kumar, 2008, Structure and clinical relevance of the epidermal growth factor receptor in human cancer, J. Clin. Oncol., 26, 1742, 10.1200/JCO.2007.12.1178 Guardiola, 2019, A third shot at EGFR: new opportunities in cancer therapy, Trends Pharmacol. Sci., 40, 941, 10.1016/j.tips.2019.10.004 Porcelli, 2014, The EGFR pathway regulates BCRP expression in NSCLC cells: role of erlotinib, Curr. Drug Targets, 15, 1322, 10.2174/1389450116666141205145620 Assaraf, 2019, The multi-factorial nature of clinical multidrug resistance in cancer, Drug Resist. Updat., 46, 100645, 10.1016/j.drup.2019.100645 Bar-Zeev, 2017, Targeted nanomedicine for cancer therapeutics: towards precision medicine overcoming drug resistance, Drug Resist. Updat., 31, 15, 10.1016/j.drup.2017.05.002 Gonen, 2012, Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance, Drug Resist. Updat., 15, 183, 10.1016/j.drup.2012.07.002 Leonetti, 2019, MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: current implications and future directions, Drug Resist. Updat., 42, 1, 10.1016/j.drup.2018.11.002 Leonetti, 2019, Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer, Drug Resist. Updat., 46, 100644, 10.1016/j.drup.2019.100644 Lepeltier, 2020, Nanomedicine to target multidrug resistant tumors, Drug Resist. Updat., 52, 100704, 10.1016/j.drup.2020.100704 Mosca, 2021, Taxanes in cancer treatment: activity, chemoresistance and its overcoming, Drug Resist. Updat., 54, 100742, 10.1016/j.drup.2020.100742 Zhitomirsky, 2016, Lysosomes as mediators of drug resistance in cancer, Drug Resist. Updat., 24, 23, 10.1016/j.drup.2015.11.004 Malapelle, 2018, Osimertinib, Recent Results Cancer Res., 211, 257, 10.1007/978-3-319-91442-8_18 Nagano, 2018, Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy, Cells, 7, 212, 10.3390/cells7110212 Wood, 2004, A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells, Cancer Res., 64, 6652, 10.1158/0008-5472.CAN-04-1168 Yun, 2007, Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity, Cancer Cell, 11, 217, 10.1016/j.ccr.2006.12.017 Wu, 2018, Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer, Mol. Cancer, 17, 38, 10.1186/s12943-018-0777-1 Soria, 2018, Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer, N. Engl. J. Med., 378, 113, 10.1056/NEJMoa1713137 Ramalingam, 2020, Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC, N. Engl. J. Med., 382, 41, 10.1056/NEJMoa1913662 Cho, 2019, Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, phase II trial (KCSG-LU15-09), J. Clin. Oncol., 38, 488, 10.1200/JCO.19.00931 Wu, 2018, CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3), J. Clin. Oncol., 36, 2702, 10.1200/JCO.2018.77.9363 Yang, 2019, Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the BLOOM study, J. Clin. Oncol., 38, 538, 10.1200/JCO.19.00457 Wu, 2020, Osimertinib in resected EGFR-mutated non-small-cell lung cancer, N. Engl. J. Med., 383, 1711, 10.1056/NEJMoa2027071 Yan, 2020, Structural basis of AZD9291 selectivity for EGFR T790M, J. Med. Chem., 63, 8502, 10.1021/acs.jmedchem.0c00891 Wang, 2020, Does the lung cancer field need another third-generation EGFR tyrosine kinase inhibitor?, J. Thorac. Oncol., 15, 881, 10.1016/j.jtho.2020.02.021 Tan, 2018, Third generation EGFR TKIs: current data and future directions, Mol. Cancer, 17, 29, 10.1186/s12943-018-0778-0 Zhang, 2020, Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance, Mol. Cancer, 19, 90, 10.1186/s12943-020-01202-9 Ricordel, 2018, Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer, Ann. Oncol., 29, i28, 10.1093/annonc/mdx705 Chen, 2018, Recent progress of small-molecule epidermal growth factor receptor (EGFR) Inhibitors against C797S resistance in non-small-cell lung cancer, J. Med. Chem., 61, 4290, 10.1021/acs.jmedchem.7b01310 Riess, 2018, Diverse EGFR exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC, J. Thorac. Oncol., 13, 1560, 10.1016/j.jtho.2018.06.019 Arcila, 2013, EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics, Mol. Cancer Ther., 12, 220, 10.1158/1535-7163.MCT-12-0620 Vyse, 2019, Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer, Signal Transduct Target Ther., 4, 5, 10.1038/s41392-019-0038-9 Naidoo, 2015, Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: clinical outcomes and response to erlotinib, Cancer, 121, 3212, 10.1002/cncr.29493 2020 Gonzalvez, 2016, AP32788, a potent, selective inhibitor of EGFR and HER2 oncogenic mutants, including exon 20 insertions, in preclinical models, Cancer Res, 76, 10.1158/1538-7445.AM2016-2644 Lovly, 2019 Yun, 2020, Antitumor activity of Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in diverse models of EGFR exon 20 insertion-driven NSCLC, Cancer Discov., 10, 1194, 10.1158/2159-8290.CD-20-0116 Cho, 2018, JNJ-61186372 (JNJ-372), an EGFR-cMET bispecific antibody, in advanced non-small cell lung cancer (NSCLC): an update on phase I results, Ann. Oncol., 29, 10.1093/annonc/mdy292.118 Haura, 2019, JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC), J. Clin. Oncol., 37, 9009, 10.1200/JCO.2019.37.15_suppl.9009 Xu, 2019, DZD9008, an oral, wild type selective EGFR inhibitor for the treatment of non-small-cell lung cancer with Exon20 insertion and other activating mutations, Cancer Res, 79, 10.1158/1538-7445.AM2019-3081 Hasako, 2018, TAS6417, a novel EGFR inhibitor targeting exon 20 insertion mutations, Mol. Cancer Ther., 17, 1648, 10.1158/1535-7163.MCT-17-1206 Udagawa, 2019, TAS6417/CLN-081 is a pan-mutation-selective EGFR tyrosine kinase inhibitor with a broad spectrum of preclinical activity against clinically relevant EGFR mutations, Mol. Cancer Res., 17, 2233, 10.1158/1541-7786.MCR-19-0419 Rolfo, 2014, Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors, Cancer Treat. Rev., 40, 990, 10.1016/j.ctrv.2014.05.009 Piotrowska, 2016, Treatment of EGFR-mutant lung cancers after progression in patients receiving first-line EGFR tyrosine kinase inhibitors : a review, JAMA Oncol., 2, 948, 10.1001/jamaoncol.2016.0333 Recondo, 2018, Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?, Nat. Rev. Clin. Oncol., 15, 694, 10.1038/s41571-018-0081-4 Cappuzzo, 2005, Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer, J. Natl. Cancer Inst., 97, 643, 10.1093/jnci/dji112 Yasuda, 2012, EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications, Lancet Oncol., 13, e23, 10.1016/S1470-2045(11)70129-2 O'Kane, 2017, Uncommon EGFR mutations in advanced non-small cell lung cancer, Lung Cancer, 109, 137, 10.1016/j.lungcan.2017.04.016 Yang, 2012, EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis, J. Hematol. Oncol., 5, 52, 10.1186/1756-8722-5-52 Barber, 2004, Somatic mutations of EGFR in colorectal cancers and glioblastomas, N. Engl. J. Med., 351, 2883, 10.1056/NEJM200412303512724 Sharafinski, 2010, Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck, Head Neck, 32, 1412, 10.1002/hed.21365 Sok, 2006, Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting, Clin. Cancer Res., 12, 5064, 10.1158/1078-0432.CCR-06-0913 Bloomston, 2006, Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique, Dig. Surg., 23, 74, 10.1159/000093497 Fjällskog, 2003, Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors, Clin. Cancer Res., 9, 1469 Lee, 2007, Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma, Cancer, 109, 1561, 10.1002/cncr.22559 Cossu-Rocca, 2016, EGFR kinase-dependent and kinase-independent roles in clear cell renal cell carcinoma, Am. J. Cancer Res., 6, 71 Ito, 2001, Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma, Br. J. Cancer, 84, 1377, 10.1054/bjoc.2000.1580 Maennling, 2019, Molecular targeting therapy against EGFR family in breast cancer: progress and future potentials, Cancers (Basel), 11, 1826, 10.3390/cancers11121826 Park, 2014, High EGFR gene copy number predicts poor outcome in triple-negative breast cancer, Mod. Pathol., 27, 1212, 10.1038/modpathol.2013.251 Teng, 2011, Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy, Breast Cancer Res., 13, R35, 10.1186/bcr2857 Nastaly, 2020, EGFR as a stable marker of prostate cancer dissemination to bones, Br. J. Cancer, 123, 1767, 10.1038/s41416-020-01052-8 Schlomm, 2007, Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer, Clin. Cancer Res., 13, 6579, 10.1158/1078-0432.CCR-07-1257 Cho, 2008, Gene amplification and mutation analysis of epidermal growth factor receptor in hormone refractory prostate cancer, Prostate, 68, 803, 10.1002/pros.20743 Kim, 2008, EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number, Histopathology, 52, 738, 10.1111/j.1365-2559.2008.03021.x Liu, 2011, Epidermal growth factor receptor mutation in gastric cancer, Pathology, 43, 234, 10.1097/PAT.0b013e328344e61b Eskilsson, 2018, EGFR heterogeneity and implications for therapeutic intervention in glioblastoma, Neuro. Oncol., 20, 743, 10.1093/neuonc/nox191 Lee, 2006, Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain, Plos Med., 3, e485, 10.1371/journal.pmed.0030485 Yang, 2019, Prognostic implications of epidermal growth factor receptor variant III expression and nuclear translocation in Chinese human gliomas, Chin. J. Cancer Res., 31, 188, 10.21147/j.issn.1000-9604.2019.01.14 Sheng, 2011, The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer, Br. J. Cancer, 104, 1241, 10.1038/bjc.2011.62 Tanaka, 2011, Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer, Cancer Biol. Ther., 11, 50, 10.4161/cbt.11.1.13877 Yang, 2015, Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6, Lancet Oncol., 16, 830, 10.1016/S1470-2045(15)00026-1 Colclough, 2021, Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs, Clin. Cancer Res., 27, 189, 10.1158/1078-0432.CCR-19-1871 Van Cutsem, 2011, Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status, J. Clin. Oncol., 29, 2011, 10.1200/JCO.2010.33.5091 Bokemeyer, 2011, Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study, Ann. Oncol., 22, 1535, 10.1093/annonc/mdq632 JY, 2014, Final results from PRIME: randomized phase 3 study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer, Ann. Oncol., 25, 1346, 10.1093/annonc/mdu141 Arnold, 2017, Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials, Ann. Oncol., 28, 1713, 10.1093/annonc/mdx175 2020 Weickhardt, 2012, Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer, J. Clin. Oncol., 30, 1505, 10.1200/JCO.2011.38.6599 Bonner, 2010, Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival, Lancet Oncol., 11, 21, 10.1016/S1470-2045(09)70311-0 Martins, 2013, Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial, J. Clin. Oncol., 31, 1415, 10.1200/JCO.2012.46.3299 C, 2019, Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, phase II clinical trial, Ann. Oncol., 30, 637, 10.1093/annonc/mdz020 2019 Schultheis, 2017, Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study, Ann. Oncol., 28, 2429, 10.1093/annonc/mdx343 Pipas, 2012, Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma, Ann. Oncol., 23, 2820, 10.1093/annonc/mds109 Philip, 2010, Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205, J. Clin. Oncol., 28, 3605, 10.1200/JCO.2009.25.7550 AH, 2016, A multicenter, open-label phase II clinical trial of combined MEK plus EGFR inhibition for chemotherapy-refractory advanced pancreatic adenocarcinoma, Clin. Cancer Res., 22, 61, 10.1158/1078-0432.CCR-15-0979 Gordon, 2009, Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317, J. Clin. Oncol., 27, 5788, 10.1200/JCO.2008.18.8821 Hainsworth, 2005, Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib, J. Clin. Oncol., 23, 7889, 10.1200/JCO.2005.01.8234 Ravaud, 2008, Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial, J. Clin. Oncol., 26, 2285, 10.1200/JCO.2007.14.5029 Philip, 2005, Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer, J. Clin. Oncol., 23, 6657, 10.1200/JCO.2005.14.696 Thomas, 2009, Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma, J. Clin. Oncol., 27, 843, 10.1200/JCO.2008.18.3301 Bekaii-Saab, 2009, A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas, Clin. Cancer Res., 15, 5895, 10.1158/1078-0432.CCR-09-0465 Dickler, 2008, A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer, Clin. Cancer Res., 14, 7878, 10.1158/1078-0432.CCR-08-0141 Smith, 2007, A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer, J. Clin. Oncol., 25, 3816, 10.1200/JCO.2006.09.6578 Arteaga, 2008, A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer, Clin. Cancer Res., 14, 6277, 10.1158/1078-0432.CCR-08-0482 Baselga, 2013, Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer, J. Clin. Oncol., 31, 2586, 10.1200/JCO.2012.46.2408 Gravis, 2008, Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer, Ann. Oncol., 19, 1624, 10.1093/annonc/mdn174 Cathomas, 2012, Efficacy of cetuximab in metastatic Castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07), Clin. Cancer Res., 18, 6049, 10.1158/1078-0432.CCR-12-2219 Piotrowska, 2018, Landscape of acquired resistance to Osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion, Cancer Discov., 8, 1529, 10.1158/2159-8290.CD-18-1022 Rangachari, 2019, EGFR-mutated lung cancers resistant to osimertinib through EGFR C797S respond to first-generation reversible EGFR inhibitors but eventually acquire EGFR T790M/C797S in preclinical models and clinical samples, J. Thorac. Oncol., 14, 1995, 10.1016/j.jtho.2019.07.016 Arulananda, 2017, Combination osimertinib and gefitinib in C797S and T790M EGFR-mutated non-small cell lung cancer, J. Thorac. Oncol., 12, 1728, 10.1016/j.jtho.2017.08.006 Zhou, 2019, Durable clinical response of lung adenocarcinoma harboring EGFR 19Del/T790M/in trans-C797S to combination therapy of first- and third-generation EGFR tyrosine kinase inhibitors, J. Thorac. Oncol., 14, e157, 10.1016/j.jtho.2019.04.020 Jia, 2016, Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors, Nature, 534, 129, 10.1038/nature17960 Uchibori, 2017, Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer, Nat. Commun., 8, 14768, 10.1038/ncomms14768 To, 2019, Single and dual targeting of mutant EGFR with an allosteric inhibitor, Cancer Discov., 9, 926, 10.1158/2159-8290.CD-18-0903 Zhang, 2018, EGFR L792H and G796R: two novel mutations mediating resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib, J. Thorac. Oncol., 13, 1415, 10.1016/j.jtho.2018.05.024 Castellano, 2019, A novel acquired exon 20 EGFR M766Q mutation in lung adenocarcinoma mediates osimertinib resistance but is sensitive to neratinib and poziotinib, J. Thorac. Oncol., 14, 1982, 10.1016/j.jtho.2019.06.015 Starrett, 2020, Drug sensitivity and allele specificity of first-line osimertinib resistance EGFR mutations, Cancer Res., 80, 2017, 10.1158/0008-5472.CAN-19-3819 Fassunke, 2018, Overcoming EGFR(G724S)-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors, Nat. Commun., 9, 4655, 10.1038/s41467-018-07078-0 Ercan, 2015, EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors, Clin. Cancer Res., 21, 3913, 10.1158/1078-0432.CCR-14-2789 Assadollahi, 2019, Interaction and molecular dynamics simulation study of osimertinib (AstraZeneca 9291) anticancer drug with the EGFR kinase domain in native protein and mutated L844V and C797S, J. Cell. Biochem., 120, 13046, 10.1002/jcb.28575 Ménard, 2018, Reactivation of mutant-EGFR degradation through clathrin inhibition overcomes resistance to EGFR tyrosine kinase inhibitors, Cancer Res., 78, 3267, 10.1158/0008-5472.CAN-17-2195 Lee, 2018, Targeting PKCdelta as a therapeutic strategy against heterogeneous mechanisms of EGFR inhibitor resistance in EGFR-mutant lung cancer, Cancer Cell, 34, 954, 10.1016/j.ccell.2018.11.007 Sun, 2020, Allosteric SHP2 inhibitor IACS-13909 overcomes EGFR-dependent and EGFR-independent resistance mechanisms towards osimertinib, Cancer Res., 80, 4840, 10.1158/0008-5472.CAN-20-1634 To, 2018, PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase inhibitors by inducing autophagy, Eur. J. Pharmacol., 823, 19, 10.1016/j.ejphar.2018.01.036 Martinez-Marti, 2017, Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC), Ann. Oncol., 28, 2451, 10.1093/annonc/mdx396 Deng, 2018, Response to dual crizotinib and osimertinib treatment in a lung cancer patient with MET amplification detected by liquid biopsy who acquired secondary resistance to EGFR tyrosine kinase inhibition, J. Thorac. Oncol., 13, e169, 10.1016/j.jtho.2018.04.007 Suzawa, 2019, Acquired MET exon 14 alteration drives secondary resistance to epidermal growth factor receptor tyrosine kinase inhibitor in EGFR-mutated lung cancer, JCO Precis Oncol., 3 Sequist, 2020, Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study, Lancet Oncol., 21, 373, 10.1016/S1470-2045(19)30785-5 Mancini, 2018, An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors, EMBO Mol. Med., 10, 294, 10.15252/emmm.201708076 Yu, 2020, LBA62 efficacy and safety of patritumab deruxtecan (U3-1402), a novel HER3 directed antibody drug conjugate, in patients (pts) with EGFR-mutated (EGFRm) NSCLC, Ann. Oncol., 31, S1189, 10.1016/j.annonc.2020.08.2295 Hsu, 2020, Exon 16-skipping HER2 as a novel mechanism of osimertinib resistance in EGFR L858R/T790M-positive non-small cell lung cancer, J. Thorac. Oncol., 15, 50, 10.1016/j.jtho.2019.09.006 Manabe, 2020, IGF2 autocrine-mediated IGF1R activation is a clinically relevant mechanism of osimertinib resistance in lung cancer, Mol. Cancer Res., 18, 549, 10.1158/1541-7786.MCR-19-0956 Hayakawa, 2020, Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation, Thorac. Cancer, 11, 140, 10.1111/1759-7714.13255 Kim, 2019, AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells, Cell Death Dis, 10, 361, 10.1038/s41419-019-1601-6 Qin, 2020, CDK4/6 inhibitor palbociclib overcomes acquired resistance to third-generation EGFR inhibitor osimertinib in non-small cell lung cancer (NSCLC), Thorac. Cancer, 11, 2389, 10.1111/1759-7714.13521 Shah, 2019, Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer, Nat. Med., 25, 111, 10.1038/s41591-018-0264-7 Nilsson, 2020, A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components, Sci. Transl. Med., 12, eaaz4589, 10.1126/scitranslmed.aaz4589 Leonetti, 2019, Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer, Br. J. Cancer, 121, 725, 10.1038/s41416-019-0573-8 Yochum, 2019, Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer, Oncogene, 38, 656, 10.1038/s41388-018-0482-y Ham, 2016, Two cases of small cell lung cancer transformation from EGFR mutant adenocarcinoma during AZD9291 treatment, J. Thorac. Oncol., 11, e1, 10.1016/j.jtho.2015.09.013 Thress, 2015, Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M, Nat. Med., 21, 560, 10.1038/nm.3854 Yu, 2015, Acquired resistance of EGFR-mutant lung cancer to a T790M-specific EGFR inhibitor: emergence of a third mutation (C797S) in the EGFR tyrosine kinase domain, JAMA Oncol., 1, 982, 10.1001/jamaoncol.2015.1066 Niederst, 2015, The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies, Clin. Cancer Res., 21, 3924, 10.1158/1078-0432.CCR-15-0560 Goldberg, 2018, Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC, PLoS ONE, 13, e0208097, 10.1371/journal.pone.0208097 Yang, 2018, Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients, Clin. Cancer Res., 24, 3097, 10.1158/1078-0432.CCR-17-2310 Chabon, 2016, Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients, Nat. Commun., 7, 11815, 10.1038/ncomms11815 Lee, 2019, Preclinical modeling of osimertinib for NSCLC with EGFR exon 20 insertion mutations, J. Thorac. Oncol., 14, 1556, 10.1016/j.jtho.2019.05.006 Callegari, 2018, L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib, Chem. Sci., 9, 2740, 10.1039/C7SC04761D Brown, 2019, On-target resistance to the mutant-selective EGFR inhibitor osimertinib can develop in an allele-specific manner dependent on the original EGFR-activating mutation, Clin. Cancer Res., 25, 3341, 10.1158/1078-0432.CCR-18-3829 Kim, 2015, Mechanisms of acquired resistance to AZD9291: a mutation-selective, irreversible EGFR inhibitor, J. Thorac. Oncol., 10, 1736, 10.1097/JTO.0000000000000688 Okura, 2020, ONO-7475, a novel AXL inhibitor, suppresses the adaptive resistance to initial EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer, Clin. Cancer Res., 26, 2244, 10.1158/1078-0432.CCR-19-2321 Papadimitrakopoulou, 2018, Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study, Ann. Oncol., 29, 10.1093/annonc/mdy424.064 Ramalingam, 2018, Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study, Ann. Oncol., 29, 10.1093/annonc/mdy424.063 Jiao, 2020, Overcoming resistance to drugs targeting KRAS(G12C) mutation, Innovation (N Y)., 1, 100035 Oxnard, 2018, Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib, JAMA Oncol., 4, 1527, 10.1001/jamaoncol.2018.2969 Le, 2018, Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC, Clin. Cancer Res., 24, 6195, 10.1158/1078-0432.CCR-18-1542 Oxnard, 2018, Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib, JAMA Oncol., 4, 1527, 10.1001/jamaoncol.2018.2969 Zeng, 2018, GOPC-ROS1 rearrangement as an acquired resistance mechanism to osimertinib and responding to Crizotinib combined treatments in lung adenocarcinoma, J. Thorac. Oncol., 13, e114, 10.1016/j.jtho.2018.02.005 Zhu, 2019, Receptor tyrosine kinase fusions as an actionable resistance mechanism to EGFR TKIs in EGFR-mutant non-small-cell lung cancer, Trends Cancer, 5, 677, 10.1016/j.trecan.2019.09.008 Shi, 2016, Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment, Cancer Lett., 380, 494, 10.1016/j.canlet.2016.07.021 Ortiz-Cuaran, 2016, Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors, Clin. Cancer Res., 22, 4837, 10.1158/1078-0432.CCR-15-1915 Romaniello, 2020, Targeting HER3, a catalytically defective receptor tyrosine kinase, prevents resistance of lung cancer to a third-generation EGFR kinase inhibitor, Cancers (Basel), 12, 2394, 10.3390/cancers12092394 Zhu, 2019, AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications, Mol. Cancer, 18, 153, 10.1186/s12943-019-1090-3 Taniguchi, 2019, AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells, Nat. Commun., 10, 259, 10.1038/s41467-018-08074-0 Blakely, 2017, Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers, Nat. Genet., 49, 1693, 10.1038/ng.3990 Mahajan, 2015, ACK1/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers, Oncogene, 34, 4162, 10.1038/onc.2014.350 Weng, 2019, Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI, Oncogene, 38, 455, 10.1038/s41388-018-0454-2 Sequist, 2011, Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors, Sci. Transl. Med., 3, 75ra26, 10.1126/scitranslmed.3002003 Lee, 2017, Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas, J. Clin. Oncol., 35, 3065, 10.1200/JCO.2016.71.9096 Niederst, 2015, RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer, Nat. Commun., 6, 6377, 10.1038/ncomms7377 Kashima, 2020, CH7233163 overcomes osimertinib resistant EGFR-Del19/T790M/C797S mutation, Mol. Cancer Ther., 19, 2288, 10.1158/1535-7163.MCT-20-0229 Liu, 2019, Preclinical evaluation of TQB3804, a potent EGFR C797S inhibitor, Cancer Res, 79 Schalm, 2020, 1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC, Ann. Oncol., 31, S839, 10.1016/j.annonc.2020.08.1610 Choe, 2017, Structure-activity relationship study of 2,4-dianilinopyrimidine containing methanesulfonamide (TRE-069) as potent and selective epidermal growth factor receptor T790M/C797S mutant inhibitor for anticancer treatment, Bull. Korean Chem. Soc., 38, 1353, 10.1002/bkcs.11287 Lu, 2018, Targeting EGFR(L858R/T790M) and EGFR(L858R/T790M/C797S) resistance mutations in NSCLC: current developments in medicinal chemistry, Med. Res. Rev., 38, 1550, 10.1002/med.21488 Lu, 2020, Medicinal chemistry strategies for the development of kinase inhibitors targeting point mutations, J. Med. Chem., 63, 10726, 10.1021/acs.jmedchem.0c00507 He, 2021, The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation, Eur. J. Med. Chem., 210, 112995, 10.1016/j.ejmech.2020.112995 Lu, 2020, Emergence of allosteric drug-resistance mutations: new challenges for allosteric drug discovery, Drug Discov. Today, 25, 177, 10.1016/j.drudis.2019.10.006 Kannan, 2018, Conformational landscape of the epidermal growth factor receptor kinase reveals a mutant specific allosteric pocket, Chem. Sci., 9, 5212, 10.1039/C8SC01262H Zhao, 2018, Crystal structure of EGFR T790M/C797S/V948R in complex with EAI045, Biochem. Biophys. Res. Commun., 502, 332, 10.1016/j.bbrc.2018.05.154 Sheikine, 2017, Clinical and technical aspects of genomic diagnostics for precision oncology, J. Clin. Oncol., 35, 929, 10.1200/JCO.2016.70.7539 Loong, 2018, Therapeutic strategies in EGFR mutant non-small cell lung cancer, Curr. Treat. Options Oncol., 19, 58, 10.1007/s11864-018-0570-9 Metzker, 2010, Sequencing technologies—the next generation, Nat. Rev. Genet., 11, 31, 10.1038/nrg2626 Zhang, 2019, Clinical management of third-generation EGFR inhibitor-resistant patients with advanced non-small cell lung cancer: current status and future perspectives, Cancer Lett., 459, 240, 10.1016/j.canlet.2019.05.044 Wang, 2018, Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial, Lancet Respir. Med., 6, 681, 10.1016/S2213-2600(18)30264-9 Zhao, 2020, Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib, Lung Cancer, 141, 114, 10.1016/j.lungcan.2019.10.021 Heitzer, 2018, Current and future perspectives of liquid biopsies in genomics-driven oncology, Nat. Rev. Genet., 20, 71, 10.1038/s41576-018-0071-5 Thress, 2015, EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291, Lung Cancer, 90, 509, 10.1016/j.lungcan.2015.10.004 Zill, 2016, Somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA, J. Clin. Oncol., 34, 10.1200/JCO.2016.34.18_suppl.LBA11501 Laufer-Geva, 2018, The clinical impact of comprehensive genomic testing of circulating cell-free DNA in advanced lung cancer, J. Thorac. Oncol., 13, 1705, 10.1016/j.jtho.2018.07.101 Remon, 2017, Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA, Ann. Oncol., 28, 784, 10.1093/annonc/mdx017 van der Pol, 2019, Toward the early detection of cancer by decoding the epigenetic and environmental fingerprints of cell-free DNA, Cancer Cell, 36, 350, 10.1016/j.ccell.2019.09.003 Wakelee, 2016, Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib, J. Clin. Oncol., 34, 9001, 10.1200/JCO.2016.34.15_suppl.9001 Reckamp, 2016, A highly sensitive and quantitative test platform for detection of NSCLC EGFR mutations in urine and plasma, J. Thorac. Oncol., 11, 1690, 10.1016/j.jtho.2016.05.035 Park, 2019, Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer, Lung Cancer, 132, 126, 10.1016/j.lungcan.2019.04.014 Misale, 2014, Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution, Cancer Discov., 4, 1269, 10.1158/2159-8290.CD-14-0462 Feng, 2020, Therapy of primary liver cancer, Innovation (N Y)., 1, 100032 Gu, 2020, RNA m6A modification in cancers: molecular mechanisms and potential clinical applications, Innovation (N Y)., 1, 100066 Dai, 2021, Small molecular NIR-II fluorophores for cancer phototheranostics, Innovation (N Y)., 2, 100082 Lu, 2020, Current status and future perspective of immunotherapy in gastrointestinal cancers, Innovation (N Y)., 1, 100041 Saito, 2019, Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial, Lancet Oncol., 20, 625, 10.1016/S1470-2045(19)30035-X Nakagawa, 2019, Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol., 20, 1655, 10.1016/S1470-2045(19)30634-5 Zhou, 2019, CTONG 1509: phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC, Ann. Oncol., 30, 10.1093/annonc/mdz260.002 Noronha, 2019, Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer, J. Clin. Oncol., 38, 124, 10.1200/JCO.19.01154 Hosomi, 2019, Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 Study, J. Clin. Oncol., 38, 115, 10.1200/JCO.19.01488 Romaniello, 2018, A combination of approved antibodies overcomes resistance of lung cancer to osimertinib by blocking bypass pathways, Clin. Cancer Res., 24, 5610, 10.1158/1078-0432.CCR-18-0450 Woodcock, 2017, Master protocols to study multiple therapies, multiple diseases, or both, N. Engl. J. Med., 377, 62, 10.1056/NEJMra1510062